|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Advances in immunotherapy for treatment of lung cancer显示文摘Different approaches for treating lung cancer have been developed over time, including chemotherapy, radiotherapy and targeted therapies against activating mutations. Lately, better understanding of the role of the immunological system in tumor control has opened multiple doors to implement different strategies to enhance immune response against cancer cells. It is known that tumor cells elude immune response by several mechanisms. The development of monoclonal antibodies against the checkpoint inhibitor programmed cell death protein 1(PD-1) and its ligand(PD-L1), on T cells, has led to high activity in cancer patients with long lasting responses. Nivolumab, an anti PD-1 inhibitor, has been recently approved for the treatment of squamous cell lung cancer patients, given the survival advantage demonstrated in a phase III trial. Pembrolizumab, another anti PD-1 antibody, has received FDA breakthrough therapy designation for treatment of non-small cell lung cancer(NSCLC), supported by data from a phase I trial. Clinical trials with anti PD-1/PD-L1 antibodies in NSCLC have demonstrated very good tolerability and activity, with response rates around 20% and a median duration of response of 18 months. | Jean G.Bustamante Alvarez María González-Cao Niki Karachaliou Mariacarmela Santarpia Santiago Viteri Cristina Teixidó Rafael Rosell | 2015 | Cancer Biology & Medicine2015，12，3： | 22 |
| 2 | Assays for predicting and monitoring responses to lung cancer immunotherapy显示文摘Immunotherapy has become a key strategy for cancer treatment, and two immune checkpoints, namely, programmed cell death 1(PD-1) and its ligand(PD-L1), have recently emerged as important targets. The interaction blockade of PD-1 and PD-L1 demonstrated promising activity and antitumor efficacy in early phase clinical trials for advanced solid tumors such as non-small cell lung cancer(NSCLC). Many cell types in multiple tissues express PD-L1 as well as several tumor types, thereby suggesting that the ligand may play important roles in inhibiting immune responses throughout the body. Therefore, PD-L1 is a critical immunomodulating component within the lung microenvironment, but the correlation between PD-L1 expression and prognosis is controversial. More evidence is required to support the use of PD-L1 as a potential predictive biomarker. Clinical trials have measured PD-L1 in tumor tissues by immunohistochemistry(IHC) with different antibodies, but the assessment of PD-L1 is not yet standardized. Some commercial antibodies lack specificity and their reproducibility has not been fully evaluated. Further studies are required to clarify the optimal IHC assay as well as to predict and monitor the immune responses of the PD-1/PD-L1 pathway. | Cristina Teixidó Niki Karachaliou Maria González-Cao Daniela Morales-Espinosa Rafael Rosell | 2015 | Cancer Biology & Medicine2015，12，2： | 10 |
| 3 | Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints显示文摘Survival rates for metastatic lung cancer, including non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC), are poor with 5-year survivals of less than 5%. The immune system has an intricate and complex relationship with tumorigenesis; a groundswell of research on the immune system is leading to greater understanding of how cancer progresses and presenting new ways to halt disease progress. Due to the extraordinary power of the immune system—with its capacity for memory, exquisite specificity and central and universal role in human biology—immunotherapy has the potential to achieve complete, long-lasting remissions and cures, with few side effects for any cancer patient, regardless of cancer type. As a result, a range of cancer therapies are under development that work by turning our own immune cells against tumors. However deeper understanding of the complexity of immunomodulation by tumors is key to the development of effective immunotherapies, especially in lung cancer. | Niki Karachaliou Maria Gonzalez Cao Cristina Teixidó Santiago Viteri Daniela Morales-Espinosa Mariacarmela Santarpia Rafael Rosell | 2015 | Cancer Biology & Medicine2015，12，2： | 10 |
| 4 | IHC、FISH和RT-PCR检测对EML4-ALK重排的一致性显示文摘棘皮动物微管结合蛋白-间变性淋巴瘤激酶(echinoderm microtubule-associated prote i n-l ike4-anaplastic lymphoma kinase,EML4-ALK)在肺癌中已成为第二个最重要的驱动致癌基因,在4%-6%的肺腺癌中EML4-ALK已经成为第一个可以靶向治疗的融合基因位点。伴随着ALK分离探针荧光原位杂交(fluorescent in situ hybridization,FISH)试剂盒的上市,克唑替尼已经被批准治疗ALK阳性的进展期非小细胞肺癌(non-small cell lung cancer,NSCLC)。然而,一种靶向药物的成功主要取决于一种敏感且特异的筛选实验方法来检测分子药物作用的靶点。以作者的经验看,用RTPCR来检测EML4-ALK,比用FISH和免疫组化(immunohistochemistry,IHC)方法更敏感,结果更可靠。尽管通过FISH检测ALK已经经过大量的临床实验验证,然而该方法在技术层面仍存在许多具有挑战性的问题,而通过IHC和RT-PCR方法检测ALK仍需要临床进一步的探索。 | Cristina Teixidó Niki Karachaliou Vicente Peg Ana Gimenez-Capitan Rafael Rosell 魏建国 许春伟 张博 | 2015 | 临床与病理杂志2015，35，2： | 3 |
| 5 | Combination of hot water, Bacillus subtilis CPA-8 and sodium bicarbonate treatments to control postharvest brown rot on peaches and nectarines 显示文摘 | Casals C Teixide N Vinas I | 2010 | European Journal of Plant Pathology2010，128，1： | 1 |
| 6 | Liquid chromatography multi-stage mass spectrometry for the analysis of 5-hydroxymethylfurfural in foods显示文摘 | Erika Teixidó Encarnación Moyano F. Javier Santos M. Teresa Galceran | 2008 | Journal of Chromatography A2008，，1： | 1 |
| 7 | Analysis of 5-hydroxymethylfurfural in foods by gas chromatography–mass spectrometry显示文摘 | E. Teixidó F.J. Santos L. Puignou M.T. Galceran | 2006 | Journal of Chromatography A2006，，1： | 1 |
| 8 | Production of the biocontrol agent Pantoea agglomerans strain CPA-2 using commercial products and by-products显示文摘 | E. Costa N. Teixidó J. Usall E. Atarés I. Vi?as | 2001 | 2001 (3-4)2001，，3： | 1 |
| 9 | Survival of the postharvest biocontrol yeast Candida sake CPA-1 after dehydration by spray-drying 显示文摘 | ABADIAS M TEIXID N USALL J | 2005 | Bio Sci Technol2005，15，8： | 1 |
| 10 | Depicting the battle between nectarine and Monilinia laxa:the fruit developmental stage dictates the effectiveness of the host defenses and the pathogen’s infection strategies显示文摘Infections by the fungus Monilinia laxa,the main cause of brown rot in Europe,result in considerable losses of stone fruit.Herein,we present a comprehensive transcriptomic approach to unravel strategies deployed by nectarine fruit and M.laxa during their interaction.We used M.laxa-inoculated immature and mature fruit,which was resistant and susceptible to brown rot,respectively,to perform a dual RNA-Seq analysis.In immature fruit,host responses,pathogen biomass,and pathogen transcriptional activity peaked at 14–24 h post inoculation(hpi),at which point M.laxa appeared to switch its transcriptional response to either quiescence or death.Mature fruit experienced an exponential increase in host and pathogen activity beginning at 6 hpi.Functional analyses in both host and pathogen highlighted differences in stage-dependent strategies.For example,in immature fruit,M.laxa unsuccessfully employed carbohydrate-active enzymes(CAZymes)for penetration,which the fruit was able to combat with tightly regulated hormone responses and an oxidative burst that challenged the pathogen’s survival at later time points.In contrast,in mature fruit,M.laxa was more dependent on proteolytic effectors than CAZymes,and was able to invest in filamentous growth early during the interaction.Hormone analyses of mature fruit infected with M.laxa indicated that,while jasmonic acid activity was likely useful for defense,high ethylene activity may have promoted susceptibility through the induction of ripening processes.Lastly,we identified M.laxa genes that were highly induced in both quiescent and active infections and may serve as targets for control of brown rot. | Marta Balsells-Llauradó Christian J.Silva Josep Usall Núria Vall-llaura Sandra Serrano-Prieto Neus Teixidó Saskia D.Mesquida-Pesci Antonieta de Cal Barbara Blanco-Ulate Rosario Torres | 2020 | Horticulture Research2020，7，1： | 1 |
| 11 | From venoms to BBB shuttles: Synthesis and blood–brain barrier transport assessment of apamin and a nontoxic analog显示文摘 | Benjamí Oller‐Salvia Meritxell Teixidó Ernest Giralt | 2013 | Biopolymers2013，，6： | 1 |
| 12 | Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C显示文摘 | A. Marco J.I. Esteban C. Solé A. da Silva J. Ortiz M. Roget C. Sarriera N. Teixidó R.A. Guerrero J.A. Caylà | 2013 | Journal of Hepatology2013，，1： | 1 |
| 13 | Effect of freeze drying and proteetants on viability of the biocontrol yeast Candida sake显示文摘 | Albadias M Benabarre A Teixid 6 N | 2001 | International Journal of Food Microbiology2001，65，3： | 1 |
| 14 | Improvement of Candida sake biocontrol activity against postharvest decay by the addition of ammonium molybdate 显示文摘 | Nunes C Usall J Teixid 6 N | 2002 | Journal of Applied Microbiology2002，92，5： | 1 |
| 15 | Sorption of Enrofloxacin and Ciprofloxacin in Agricultural Soils: Effect of Organic Matter显示文摘 | Marc Teixidó Joana Medeiros José L. Beltrán Maria-Dolors Prat Mercè Granados | 2014 | Adsorption Science & Technology2014，，2： | 1 |
| 16 | Predicting contaminant adsorption in black carbon (biochar)-amended soil for the veterinary antimicrobial sulfamethazine显示文摘 | Teixidó M Hurtado C Pignatello J J | 2013 | Environmental Science & Technology2013，47，3： | 1 |
| 17 | Sorption of tetracyclines onto natural soils:data analysis and prediction显示文摘 | TeixidóM Granados M Prat M D | 2012 | Environmental Science and Pollution Research2012，19，8： | 1 |
| 18 | Liquid formulation of the biocontrol agent Candida sake by modifying water activity or adding protectants 显示文摘 | Torres R Usall J Teixidó N | 2003 | Journal of Applied Microbiology2003，94，2： | 1 |
| 19 | RGS10 restricts up-regulation by chemokines of T cell adhesion mediated by α4β1 andαLβ2 integrins显示文摘 | García-Bernal D Dios-Esponera A Sotillo-Mallo E García-Verdugo R Arellano-Sánchez N Teixidó J | | 0，，： | 1 |
| 20 | Production of the biocontrol agent Pantoea agglomerans strain CPA-2 using commercial products and by-products显示文摘 | E. Costa N. Teixidó J. Usall E. Atarés I. Vi?as | 2001 | Applied Microbiology and Biotechnology (-)2001，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员